» Articles » PMID: 31343468

Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis

Abstract

Introduction: In patients with ulcerative colitis (UC), dysplasia develops in 10%-20% of cases. The persistence of low-grade dysplasia (LGD) in UC in 2 consecutive observations is still an indication for restorative proctocolectomy. Our hypothesis is that in the case of weak cytotoxic activation, dysplasia persists. We aimed to identify possible immunological markers of LGD presence and persistence.

Methods: We prospectively enrolled 112 UC patients who underwent screening colonoscopy (T0) who had biopsies taken from their sigmoid colon. Ninety of them had at least a second colonoscopy (T1) with biopsies taken in the sigmoid colon and 8 patients had dysplasia in both examinations suggesting a persistence of LGD in their colon. Immunohistochemistry and real time polymerase chain reaction for CD4, CD69, CD107, and CD8β messenger RNA (mRNA) expression and flow cytometry for epithelial cells expressing CD80 or HLA avidin-biotin complex were performed. Non-parametric statistics, receiver operating characteristic curves analysis, and logistic multiple regression analysis were used.

Results: Thirteen patients had LGD diagnosed at T0. The mucosal mRNA expression of CD4, CD69, and CD8β was significantly lower than in patients without dysplasia (P = 0.033, P = 0.046 and P = 0.007, respectively). A second colonoscopy was performed in 90 patients after a median follow-up of 17 (12-25) months and 14 of the patients were diagnosed with LGD. In these patients, CD8β mRNA expression at T0 was significantly lower in patients without dysplasia (P = 0.004). A multivariate survival analysis in a model including CD8β mRNA levels and age >50 demonstrated that both items were independent predictors of dysplasia at follow-up (hazard ratio [HR] = 0.47 [95% confidence interval [CI]: 0.26-0.86], P = 0.014, and HR = 13.32 [95% CI: 1.72-102.92], P = 0.013).

Discussion: These data suggest a low cytotoxic T cell activation in the colonic mucosa of UC patients who do not manage to clear dysplasia. Thus, low level of CD8β mRNA expression in non-dysplastic colonic mucosa might be considered in future studies about the decision making of management of LGD in UC.

Citing Articles

IMMUNOREACT 9 metachronous rectal cancers have high HLA-ABC expression on healthy epithelium but a lower infiltration of CD3+ T cells than primary lesions.

Salmaso B, Scarpa M, Pellegrini V, Stepanyan A, Salmaso R, Kotsafti A Sci Rep. 2024; 14(1):29821.

PMID: 39616209 PMC: 11608249. DOI: 10.1038/s41598-024-80299-0.


Lymphocyte subsets for predicting inflammatory bowel disease progression and treatment response: a systematic review.

Chen R, Li C, Zheng J, Fan Z, Li L, Chen M Front Immunol. 2024; 15:1403420.

PMID: 39229260 PMC: 11368782. DOI: 10.3389/fimmu.2024.1403420.


Genomic insights into pediatric intestinal inflammatory and eosinophilic disorders using single-cell RNA-sequencing.

Keever-Keigher M, Harvey L, Williams V, Vyhlidal C, Ahmed A, Johnston J Front Immunol. 2024; 15:1420208.

PMID: 39192974 PMC: 11347318. DOI: 10.3389/fimmu.2024.1420208.


Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response.

Kotsafti A, Scarpa M, Cavallin F, Fassan M, Salmaso R, Porzionato A Oncoimmunology. 2020; 9(1):1804169.

PMID: 32923165 PMC: 7458640. DOI: 10.1080/2162402X.2020.1804169.

References
1.
Lim C, Dixon M, Vail A, Forman D, Lynch D, Axon A . Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut. 2003; 52(8):1127-32. PMC: 1773763. DOI: 10.1136/gut.52.8.1127. View

2.
Chen L, Ashe S, Brady W, Hellstrom I, Hellstrom K, Ledbetter J . Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992; 71(7):1093-102. DOI: 10.1016/s0092-8674(05)80059-5. View

3.
Choi C, Ignjatovic-Wilson A, Askari A, Lee G, Warusavitarne J, Moorghen M . Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer. Am J Gastroenterol. 2015; 110(10):1461-71. PMC: 4697133. DOI: 10.1038/ajg.2015.248. View

4.
Itzkowitz S . Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. J Clin Gastroenterol. 2003; 36(5 Suppl):S70-4; discussion S94-6. DOI: 10.1097/00004836-200305001-00012. View

5.
Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S . Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003; 125(5):1311-9. DOI: 10.1016/j.gastro.2003.08.023. View